4153.TWO DIVA Laboratories Ltd
- Market cap
- TWD 1.77B
- P/E
- 15.5x
- P/B
- 1.85x
- ROE
- 11.4%
- Dividend yield
- 6.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 4153.TWO undervalued?
Graham number4153.TWO trades 12.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DIVA Laboratories Ltd fundamental analysis
No fundamental analysis for DIVA Laboratories Ltd yet.
DIVA Laboratories Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is headquartered in New Taipei City, Taiwan.
Full company profileDIVA Laboratories Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DIVA Laboratories Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 857M | 650M | 716M | 737M | 712M | 949M | 894M | 862M | 869M | 955M |
| Gross Profit | 182M | 205M | 225M | 214M | 182M | 266M | 251M | 260M | 264M | 283M |
| Operating Income | -43.4M | 45.4M | 64.6M | 58.7M | 24.7M | 122M | 96.6M | 103M | 109M | 118M |
| EBITDA | -258M | 80.2M | 84.1M | 77.7M | 38.4M | 132M | 97.2M | 127M | 119M | 139M |
| Net Income | -267M | 52.2M | 56.0M | 17.4M | 21.9M | 49.7M | 73.6M | 93.7M | 90.5M | 114M |
| EPS | -5.93 | 0.87 | 0.78 | 0.26 | 0.37 | 0.84 | 1.25 | 1.60 | 1.54 | 1.94 |
| Balance Sheet | ||||||||||
| Total Assets | 1.06B | 1.32B | 1.30B | 1.11B | 1.18B | 1.25B | 1.24B | 1.31B | 1.35B | 1.36B |
| Total Liabilities | 255M | 139M | 168M | 124M | 195M | 236M | 211M | 250M | 325M | 363M |
| Shareholders' Equity | 807M | 1.18B | 1.13B | 989M | 986M | 1.02B | 1.03B | 1.06B | 1.03B | 997M |
| Cash & Short-term Investments | 281M | 611M | 561M | 329M | 300M | 346M | 537M | 589M | 494M | 438M |
| Total Debt | - | - | 21.0K | 537K | 411K | 283K | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 41.4M | 86.0M | 52.7M | -16.6M | -11.4M | 73.2M | 253M | 123M | 20.8M | 86.6M |
| Capital Expenditure | 13.3M | 21.7M | 12.8M | 21.8M | 12.9M | 11.4M | 7.69M | 2.13M | 1.00M | 7.75M |
| Free Cash Flow | 23.1M | 61.8M | 39.9M | -38.4M | -24.2M | 61.8M | 245M | 121M | 19.8M | 78.8M |
| Ratios | ||||||||||
| ROE | -33.1% | 4.4% | 4.9% | 1.8% | 2.2% | 4.9% | 7.1% | 8.9% | 8.8% | 11.4% |
| ROA | -25.2% | 3.9% | 4.3% | 1.6% | 1.8% | 4.0% | 5.9% | 7.2% | 6.7% | 8.4% |
| Net Profit Margin | -31.2% | 8.0% | 7.8% | 2.4% | 3.1% | 5.2% | 8.2% | 10.9% | 10.4% | 11.9% |
| Debt to Equity | - | - | 0.00x | 0.00x | 0.00x | 0.00x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DIVA Laboratories Ltd dividends
- Dividend yield
- 6.61%
- Forward dividend
- 2.00 TWD
- Payout ratio
- 129.6%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 117M | 2.00 | 129.6% |
| 2024 | TWD 73.3M | 1.25 | 78.3% |
| 2023 | TWD 58.7M | 1.00 | 79.7% |
| 2022 | TWD 21.7M | 0.37 | 43.7% |
| 2021 | TWD 15.3M | 0.26 | 69.8% |
| 2020 | TWD 15.3M | 0.23 | 87.6% |
| 2019 | TWD 107M | 1.48 | 190.2% |
| 2018 | TWD 107M | 1.77 | 204.4% |
| 2017 | TWD 107M | 2.37 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 834.2489:1000 on Oct 8, 2020.
Who owns DIVA Laboratories Ltd
- Insiders 71.46%
- Institutions 0.00%
- Public & others 28.54%
- Shares outstanding 58.7M
- Free float 22.3M
DIVA Laboratories Ltd company profile
- Company name
- DIVA Laboratories Ltd
- Ticker
- 4153.TWO
- ISIN
- TW0004153002
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 351, Zhongshan Rd., New Taipei City, Taiwan, 235602
- Phone
- 886 2 2226 8631
- Website
- diva.com.tw
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is headquartered in New Taipei City, Taiwan.
DIVA Laboratories Ltd management
7- Mr. Chen GeneVice Chairman & CEO
- Peter ChangChief Operating Officer
- Su Ru LinAccounting Supervisor
- James ChenVP & CTO
- Jun Xian LiDirector of the Information Department
- Jian Gen ZhangDeputy General Manager of the Development Department
- Kenneth ChenChief SO